The benefits and side effects of gadolinium-based contrast agents in multiple sclerosis patients
AUTOR(ES)
Asadollahzade, Elnaz; Ghadiri, Fereshteh; Ebadi, Zahra; Moghadasi, Abdorreza Naser
FONTE
Revista da Associação Médica Brasileira
DATA DE PUBLICAÇÃO
2022
RESUMO
Documentos Relacionados
- Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines
- Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis.
- THE EFFECTS OF INDUCED HYPERTHERMIA ON PATIENTS WITH MULTIPLE SCLEROSIS*
- Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis.
- Contrast-enhanced lesions on computerised tomography in multiple sclerosis.